Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A 02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers

Next Previous
Trial Profile

A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A 02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KITE 439 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications Cancer; Cervical cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Kite Pharma

Most Recent Events

  • 22 Dec 2023 Number of Treatment arms has been changed to 7, Interventional study model has been changed to sequential from single group assignment.
  • 19 May 2022 Status changed from active, no longer recruiting to discontinued. Reason: Development program terminated.
  • 24 Jan 2022 Planned End Date changed from 1 Mar 2022 to 1 May 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top